Novo Nordisk A/S
NYSE:NVODrug Manufacturers - General
-$0.48 today
- Market cap
- $173.82B
- Beta
- 0.35
- P/E (TTM)
- 10.2
- EPS (TTM)
- $27.45
- Dividend yield
- 4.18%
Volume 16.12M
Average 16.05M
NVO Research & Development
Spending on developing new products, technologies, and improvements to existing offerings.
Novo Nordisk A/SNYSE: NVO
Research & Development · Q2 FY2026 · quarter ended Jun 2026
Research & development growth accelerates
Q2 FY2026 research & development of DKK 17.79B rose 52.2% year over year, ahead of the +28.3% change in trailing-twelve-month research & development. Sequentially, it rose 73.0% from the prior quarter. Over 3 fiscal years it compounded at +29.3% a year.
Context
- Research & development amounted to 16.8% of revenue in FY2025, up 0.3 pp from a year earlier.
- Research & development increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +52.2% holds above the trailing-twelve-month pace of +28.3%.
Sources:Income StatementText generated from reported figures; not investment advice.
Research & Development history
DKK · from the income statement
- Latest · FY2025
- 52.04B DKK
- Year-over-year change
- +8.3%
- 4-year CAGR
- +30.8%
| Period | Period end | Research & Development | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 52.04B | +8.3% |
| FY2024 | 2024-12-31 | 48.06B | +48.1% |
| FY2023 | 2023-12-31 | 32.44B | +34.9% |
| FY2022 | 2022-12-31 | 24.05B | +35.3% |
| FY2021 | 2021-12-31 | 17.77B | — |
Research & Development vs competitors
How NVO compares with its peers on the latest reported figures
- Peers report in different currencies, so research & development is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +28.3% is the 3rd highest of 10, against a peer median of +7.0%.
- Research & development amounts to 17.6% of revenue for NVO, versus a peer median of 18.3%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | DKK 58.11B DKK | +28.3% | +29.3% | 17.6% | |
| LTM Jun 2026 | $28.35B USD | +65.7% | -2.6% | 42.7% | |
| LTM Sep 2026 | $16.08B USD | +2.4% | +1.2% | 16.2% | |
| LTM Sep 2026 | $15.01B USD | -0.3% | +13.4% | 24.1% | |
| LTM Jun 2026 | $14.6B USD | +23.4% | +22.9% | 18.3% | |
| LTM Jun 2026 | $11.05B USD | +7.0% | -3.0% | 17.3% | |
| LTM Sep 2026 | $9.96B USD | -25.0% | +11.8% | 15.1% | |
| LTM Jun 2026 | £9.2B GBP | +31.8% | +11.1% | 27.7% | |
| LTM Jun 2026 | €8.11B EUR | +5.4% | +6.5% | 16.6% | |
| LTM Jun 2026 | $7.64B USD | +19.3% | +16.3% | 20.0% | |
| Peer median (excluding NVO) | — | +7.0% | +11.1% | 18.3% | |
Competitors are the stored peer set for NVO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 140.8B | 176.95B | 232.26B | 290.4B | 309.06B |
| Cost of Revenue | 23.66B | 28.45B | 35.77B | 44.52B | 58.79B |
| Gross Profit | 117.14B | 148.51B | 196.5B | 245.88B | 250.28B |
| Gross Margin | 83.2% | 83.9% | 84.6% | 84.7% | 81.0% |
| Research & Development | 17.77B | 24.05B | 32.44B | 48.06B | 52.04B |
| Selling, General & Admin | 41.06B | 50.68B | 61.6B | 67.38B | 70.28B |
| Operating Expenses | 58.5B | 73.7B | 93.92B | 117.54B | 122.62B |
| Depreciation & Amortization | 6.03B | 7.36B | 9.41B | 19.11B | 21.98B |
| EBITDA | 65.39B | 76.8B | 114.63B | 147.94B | 156.73B |
| EBITDA Margin | 46.4% | 43.4% | 49.4% | 50.9% | 50.7% |
| Operating Income | 58.64B | 74.81B | 102.57B | 128.34B | 127.66B |
| Operating Margin | 41.7% | 42.3% | 44.2% | 44.2% | 41.3% |
| Interest Income | 231M | 239M | 1.07B | 1.84B | 1.27B |
| Interest Expense | 289M | 378M | 542M | 1.64B | 4.21B |
| Other Income / Expenses | 436M | (5.75B) | 2.1B | (1.15B) | 2.88B |
| Income Before Tax | 59.08B | 69.06B | 104.67B | 127.19B | 130.54B |
| Pre-Tax Margin | 42.0% | 39.0% | 45.1% | 43.8% | 42.2% |
| Income Tax Expense | 11.32B | 13.54B | 20.99B | 26.2B | 28.11B |
| Net Income | 47.76B | 55.53B | 83.68B | 100.99B | 102.43B |
| Net Margin | 33.9% | 31.4% | 36.0% | 34.8% | 33.1% |
| EPS (Basic) | 10.40 | 12.26 | 18.67 | 22.67 | 23.06 |
| EPS (Diluted) | 10.37 | 12.22 | 18.62 | 22.63 | 23.03 |
| Weighted Avg Shares | 4.59B | 4.53B | 4.48B | 4.45B | 4.45B |
| Weighted Avg Shares (Diluted) | 4.61B | 4.54B | 4.49B | 4.46B | 4.45B |
Novo Nordisk A/S
NYSE:NVO
Intrinsic Alpha fair value
Locked
Current Price
$39.43
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.